With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. | With the ink barely dry on outgoing commissioner Marty ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | ...
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and ...
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in ...
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ...
As biologics have come to supersede small molecules in the biopharma industry’s pipeline, the mounting complexity behind the ...
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...
A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results